恩替卡韦与阿德福韦酯治疗慢性乙肝所致不良反应情况的比较

Comparison of incidence rate of adverse effects induced by entecavir and adefovir dipivoxil in the treatment of patients with chronic hepatitis B

目的:评价恩替卡韦与阿德福韦酯治疗核苷初治的慢性乙型肝炎的不良反应发生率。方法:检索2003年1月–2010年5月公开发表的恩替卡韦每天0.5mg与阿德福韦酯每天10mg治疗核苷初治的慢性乙型肝炎(疗程≥48周)的随机对照临床研究。采用χ2检验分析研究间的异质性,以相对危险度为疗效分析统计量进行合并分析并绘制森林图。结果:最终纳入1篇英文文献,4篇中文文献。分析结果显示,恩替卡韦治疗组和阿德福韦酯治疗组12周和48周时不良反应发生率的差异无统计学意义(P值分别为0.50和0.92)。结论:恩替卡韦和阿德福韦酯治疗核苷初治的慢性乙型肝炎的不良反应发生率相似。

Objective：To evaluate the incidence rate of adverse effects induced by entecavir and adefovir dipivoxil in nucleoside-naive patients with chronic hepatitis B.Methods：Randomized controlled clinical trials published between January 2003 and May 2010 about comparison of efficacy between entecavir and adefovir dipivoxil in nucleoside-naive patients with chronic hepatitis B were searched.The dosages of entecavir and adefovir dipivoxil were 0.5 mg each day and 10 mg each day respectively,and the courses of treatment were no less than 48 weeks.Heterogeneity was examined by Chi-square test,the relative risk was calculated and forest-graph was drawn.Results：One English article and four Chinese articles were included.Results of meta analysis showed that there was no significant difference in the incidence rate of adverse effect at 12 weeks（P = 0.50） and 48 weeks（P = 0.92） between the entecavir group and adefovir dipivoxil group.Conclusion：There was similar incidence rate of adverse effect between entecavir and adefovir dipivoxil in nucleoside-naive patients with chronic hepatitis B.